$Rig's Platinum Penny Alerts

[grizzy]

~IGTG news

- Gross Profits Increase More Than 400% -

CALIMESA, Calif., Jan. 13 /PRNewswire-FirstCall/ -- Ingen Technologies,
Inc. (OTC: IGTG), a medical device manufacturer of OxyAlert(TM), OxyView(TM),
and Secure Balance(TM), announces substantial increases in revenues and gross
profits.
The revenues for the six months ended November 30, 2005 were $767,084, as
compared to the previous year of $223,293. Gross Profits for the six months
ended November 30, 2005 were $573,025 as compared to the previous year of
$128,046.
The company has invested more than $6,000,000 in the research and
development of the product lines, including OxyView(TM) and OxyAlert(TM).
During the six months ended November 30, 2005, the company incurred
substantial costs to complete OxyView(TM) and continue completion of the
OxyAlert(TM) products.
Scott Sand, CEO & Chairman stated: "The revenues for Secure Balance(TM)
sales have increased more than 300%, and the Gross Profits have increased even
greater. With a focused emphasis on completing all of the SEC Filings, we
anticipate a very smooth transition to the OTCBB."
"The reason for the change in retail pricing of the OxyView(TM) was due to
the unexpected change in manufacturing costs for OxyView(TM). The current
retail pricing of $14.95 is a result of the decrease in manufacturing costs.
The company has created a 4+4 Class-A steal mold with special features that
have substantially decreased manufacturing costs as compared to the costs
published last July-2005 when we released a retail price of $75. This change
in retail pricing allows for a more affordable product for hospitals, surgical
centers and patients, as well as a higher margin and profit for the company,"
said Thomas Neavitt, Chief Financial Officer.

About Ingen Technologies, Inc.
Ingen Technologies, Inc. is a public company trading under
NASDAQ OTC: IGTG, which has been in business since 1999. IGTG is a medical
device manufacturer and a growth-oriented company that owns US patent(s),
trademarks, and proprietary medical products.
The Company's flagship product is OxyAlert(TM), a second-generation design
of the Company's BAFI(TM) product line. Both of these products have been
issued two US Patents: Patent No. 6,137,417 issued on October 24, 2000 and
Patent No. 6,326,896 issued on December 4, 2001. Both of these products are
low-oxygen safety warning devices used on remote oxygen cylinders for
patients, commercial aircraft, military transport, and fire and safety
equipment. OxyAlert(TM) technology encompasses the use of digital sensing and
RF frequency transfer so that care givers can access a hand-held remote to
monitor the actual oxygen level of any oxygen cylinder at a reasonable
distance.
The newest product, OxyView(TM), has a patent pending, and is a pneumatic
gauge that provides visual safety warning of oxygen flow to hospitalized
patients. This product enhances the safety, assurance and accuracy of
hospitalized patients being administered oxygen from any source. OxyView(TM)
is a lightweight pneumatic gauge that is attached to the oxygen tubing just
below the neck. It informs the nursing staff of oxygen flow rate near the
patient. It could quickly inform the hospital staff of any leak or inaccuracy
between the delivery source and the patient.
The Secure Balance(TM) product is a private-label product that includes a
vestibular function testing system and balance therapy system. The vestibular
function testing system is manufactured by Interacoustics LTD. in Denmark and
is referred to as the VNG. The balance therapy system is manufactured by
SportKAT(R), Inc. in San Diego, California. The Secure Balance(TM) program
provides equipment, education and training about balance and fall prevention
to physicians and clinicians worldwide.
The Pure Produce(TM) product is a continuing research & development
program currently under design. This program uses hydroponics technology to
grow various plants without the use of soil, fertilizer and water consumption.
The Company anticipates entering the nutriceutical and pharmaceutical markets
over the next two years.
"Our team of professionals has developed our medical products for the
ever-increasing elderly population. Our products are superior to any of our
competition and they allow for effective medical product availability to
seniors, and at the same time the increasing senior population allows for a
steady growth in sales and profits," said Scott Sand, CEO & Chairman of Ingen
Technologies.

For more information, visit http://www.ingen-tech.com

Investor Relations Contact: Scott R. Sand, C.E.O & Chairman
Ingen Technologies, Inc. -
Administrative Office
35193 Avenue "A", Suite-C
Yucaipa, California 92399
Phone: [phone] or [phone]
Fax: [phone] or [phone]
Email: [e-mail]
A Member of the Better Business Bureau
A Member of the Chamber of Commerce
A Licensed Business in the City of Yucaipa

Safe Harbor for Forward-Looking Statements: This news release includes
forward-looking statements that are made pursuant to "Safe Harbor" provisions
of the Private Securities Litigation Reform Act of 1995. While these
statements are made to convey to the public the company's progress, business
opportunities and growth prospects, readers are cautioned that such
forward-looking statements represent management's opinion. Whereas management
believes such representations to be true and accurate based on information and
data available to the company at this time, actual results may differ
materially from those described. The company's operations and business
prospects are always subject to risk and uncertainties. Important factors
that may cause actual results to differ will be set forth in the company's
periodic filings with the U.S. Securities and Exchange Commission.


SOURCE Ingen Technologies, Inc.
Web Site: http://www.ingen-tech.com